M&A insights for 2024

Financial sponsors are targeting proprietary data sets that can be used to customize pre-trained AI models, but must be wary of the resulting data privacy, IP and regulatory risks.

Listed and private asset managers are seeking acquisitions of smaller rivals and specialist boutiques to build assets under management (AUM) and expand their strategic focus. When executing deals, they need to consider how changes in control can impact capital redemptions and retention of star managers, or trigger regulatory challenges. 

Faced with a significant “patent cliff” and following a series of completed blockbuster M&A deals as well as a more hostile antitrust environment, the next wave of deal activity in life sciences is set to center on big players bidding for biotechs and mid-tier companies.